Welcome to our dedicated page for Chembio Diagnostics news (Ticker: CEMI), a resource for investors and traders seeking the latest updates and insights on Chembio Diagnostics stock.
Chembio Diagnostics, Inc. (CEMI) delivers rapid diagnostic solutions through its proprietary DPP technology, serving healthcare providers and public health organizations worldwide. This dedicated news hub provides investors and industry professionals with essential updates on financial developments, product innovations, and strategic partnerships.
Access real-time press releases covering earnings reports, regulatory milestones, and leadership changes, including recent executive appointments impacting the diagnostics sector. Discover updates on Chembio's expanding portfolio of infectious disease tests for COVID-19, tropical fevers, and STDs, all critical tools for modern healthcare systems.
Our curated news collection enables informed decision-making by tracking operational expansions, technology licensing agreements, and collaborations with global health authorities. Bookmark this page for direct access to verified updates about Chembio's market position and contributions to point-of-care diagnostics.
Chembio Diagnostics, a leader in point-of-care diagnostics, announced participation in two investor conferences. The management team will attend the virtual 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020, followed by the Benchmark Healthcare House Call Virtual Conference on June 16, 2020. Notably, these events do not include webcasts. Chembio specializes in diagnosing infectious diseases, leveraging its patented DPP technology for rapid testing. Their products cater to diverse markets including hospitals, clinics, and consumers.
Chembio Diagnostics, Inc. (CEMI) announced a multi-year, non-exclusive agreement with Thermo Fisher Scientific’s healthcare channel to distribute its DPP COVID-19 System in the U.S. This rapid serological test delivers results for IgM and IgG antibody levels within 15 minutes using a finger stick blood sample. The partnership aims to enhance Chembio's market reach, providing access to numerous hospital and physician office labs. A dedicated training and marketing initiative for the Fisher Healthcare team is set to begin, promoting effective product coverage.
Chembio Diagnostics (CEMI) closed its public offering of 2,619,593 shares at $11.75 per share, generating approximately $30.8 million in gross proceeds. The offering included an additional 281,125 shares as part of the underwriters' option. The funds will support a strategic refocus on manufacturing and commercializing the DPP COVID-19 System, expanding the sales force, and increasing manufacturing capacity. This offering is conducted under an effective shelf registration statement with the SEC.
Chembio Diagnostics (CEMI) has announced a public offering of 2,338,468 shares of its common stock at $11.75 per share, raising approximately $27.5 million. The underwriters also have the option to purchase an additional 350,770 shares. The offering is expected to close around May 11, 2020. Chembio plans to use the net proceeds to refocus its business strategy, enhance manufacturing capacity, and support marketing efforts for its DPP COVID-19 System, along with general corporate purposes.
Chembio Diagnostics, Inc. (Nasdaq: CEMI) announced a proposed public offering of an undetermined number of shares of common stock to support its business strategy refocus. The proceeds will finance the manufacturing and commercialization of the DPP COVID-19 System, expand the sales force, and enhance manufacturing capacity. The offering is subject to market conditions and will include a 30-day option for underwriters to purchase additional shares. Baird serves as the sole book-running manager, with Dougherty & Company as co-manager.
Chembio Diagnostics, Inc. (CEMI) reported Q1 2020 financial results with total revenue of $6.9 million, a 20% decline year-over-year. Product revenue fell 14% to $5.7 million, while combined license, royalty, and R&D revenue plummeted 40% to $1.1 million. The company recognized a net loss of $5.0 million, or $(0.29) per diluted share, compared to $(0.16) in the prior year. Despite these challenges, Chembio received FDA Emergency Use Authorization for its DPP COVID-19 IgM/IgG System, and reported a significant purchase order of $4.0 million from Bio-Manguinhos, marking key developments in their COVID-19 response.
Chembio Diagnostics, Inc. (CEMI) announced on May 4, 2020, that it has received the CE Marking for its DPP COVID-19 System, enabling commercialization in the EU and the Caribbean. CEO Rick Eberly highlighted that this achievement significantly expands market opportunities for their rapid serological test. The system, which provides IgM and IgG antibody readings from a finger stick in 15 minutes, is already authorized for use in the U.S. and Brazil. Chembio is focused on diagnosing infectious diseases and continues to support decentralized testing for ongoing demand.
